Detailed Narrative
Strategic Pivot to High-Acuity Care Drives ARPOB
Aster achieved a milestone ARPOB of over ₹50,000, a 14% YoY increase. This was driven by a deliberate shift toward high-value specialties like Oncology, which now accounts for 11% of revenue compared to 9% in Q1 FY24. Additionally, the company improved operational efficiency by reducing ALOS from 3.2 to 3.1 days, effectively increasing capacity without adding physical beds.
Aggressive Bengaluru Expansion Strategy
Management is doubling down on the Bengaluru market, adding 1,439 beds including a new 500-bed facility in Yeswanthpur. Once complete, total capacity in the city will exceed 2,580 beds. This strategy aims to capture localized demand in a city where traffic makes travel difficult, positioning Aster as a top 3 healthcare provider in the region.
QCIL Merger Synergies Materializing Early
The proposed merger with Quality Care India Limited (QCIL) is already yielding results through pre-merger synergies. QCIL reported a ₹20 crore EBITDA uplift this quarter solely from centralized procurement and formulary compliance across its Care, KIMS, and Evercare entities. The combined entity will boast 10,350 beds across 38 hospitals, with proforma revenues of ₹2,157 crores.
Kerala Cluster Stabilizes After Leadership Changes
After several challenging quarters, the Kerala cluster saw a 5% YoY revenue growth and an 11% sequential improvement. Management attributed this to stabilized leadership and a 12% sequential jump in Medical Value Travel (MVT) revenues. The cluster maintained a healthy EBITDA margin of approximately 25% during the quarter.
Aster Labs and Pharmacy Turnaround
Aster Labs saw its EBITDA margins more than double to 7.6% from 3.4% a year ago, supported by a 46% growth in external business and material cost efficiencies. In the pharmacy segment, the company strategically exited loss-making wholesale segments, allowing the business to achieve EBITDA break-even this quarter.